Cargando…
Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264419/ https://www.ncbi.nlm.nih.gov/pubmed/24619079 http://dx.doi.org/10.1038/bjc.2014.115 |
| _version_ | 1782348738982838272 |
|---|---|
| author | Spindler, K-L G Pallisgaard, N Andersen, R F Jakobsen, A |
| author_facet | Spindler, K-L G Pallisgaard, N Andersen, R F Jakobsen, A |
| author_sort | Spindler, K-L G |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4264419 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42644192014-12-16 Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' Spindler, K-L G Pallisgaard, N Andersen, R F Jakobsen, A Br J Cancer Letter to the Editor Nature Publishing Group 2014-12-09 2014-03-11 /pmc/articles/PMC4264419/ /pubmed/24619079 http://dx.doi.org/10.1038/bjc.2014.115 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
| spellingShingle | Letter to the Editor Spindler, K-L G Pallisgaard, N Andersen, R F Jakobsen, A Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' |
| title | Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' |
| title_full | Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' |
| title_fullStr | Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' |
| title_full_unstemmed | Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' |
| title_short | Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' |
| title_sort | response to comment on ‘kras-mutated plasma dna as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264419/ https://www.ncbi.nlm.nih.gov/pubmed/24619079 http://dx.doi.org/10.1038/bjc.2014.115 |
| work_keys_str_mv | AT spindlerklg responsetocommentonkrasmutatedplasmadnaaspredictorofoutcomefromirinotecanmonotherapyinmetastaticcolorectalcancer AT pallisgaardn responsetocommentonkrasmutatedplasmadnaaspredictorofoutcomefromirinotecanmonotherapyinmetastaticcolorectalcancer AT andersenrf responsetocommentonkrasmutatedplasmadnaaspredictorofoutcomefromirinotecanmonotherapyinmetastaticcolorectalcancer AT jakobsena responsetocommentonkrasmutatedplasmadnaaspredictorofoutcomefromirinotecanmonotherapyinmetastaticcolorectalcancer |